natgillin/translations-raw huggingface dataset:
Oprymea 0.35 mg tablets are white, oval, with bevelled edges, both sides scored, with imprint "P8" on both halves of one side of the tablet. 
Oprymea 0,35 mg tabletter: vit, oval, fasade kanter, brytskåra på båda sidorna, märkta med “P8” på båda halvorna på ena sidan.
1 tablet Oprymea 0.18 mg three times a day OR 
1 tablett Oprymea 0,18 mg 3 gånger dagligen eller
1 tablet Oprymea 0.088 mg three times a day 
1 tablett Oprymea 0,088 mg 3 gånger dagligen
3 tablets Oprymea 0.18 mg OR 
3 tabletter Oprymea 0,18 mg eller
Oprymea 1.05 mg: Each prolonged-release tablet contains 1.05 mg pramipexole (as 1.5 mg pramipexole dihydrochloride monohydrate). 
Oprymea 1,05 mg: Varje depottablett innehåller 1,05 mg pramipexol (vilket motsvarar 1,5 mg pramipexoldihydrokloridmonohydrat).
Not known: - After stopping or reducing your Oprymea treatment: Depression, apathy, anxiety, fatigue, 
Ingen känd frekvens: - Efter att behandling med Oprymea satts ut eller trappats ner: depression, apati, ångest, trötthet, svettningar eller smärta kan förekomma (utsättningssyndrom efter behandling med dopaminagonist).
Doses should be increased gradually from a starting dose of 0.26 mg of base (0.375 mg of salt) per day and then increased every 5 - 7 days. 
Dosen ökas gradvis från en initialdos på 0,26 mg bas (0,375 mg salt) per dag, med dosökning var femte till var sjunde dag.
This side effect has been observed in post-marketing experience. 
En biverkan som observerats efter att produkten kommit ut på marknaden.
White, oval, with bevelled edges, both sides scored, with imprint "P7" on both halves of one side of the tablet. 
Vit, oval, fasade kanter med brytskåra, märkta med “P7” på båda halvorna på ena sidan.
Oprymea 0.18 mg tablets are white, oval, with bevelled edges, both sides scored, with imprint "P7" on both halves of one side of the tablet. 
Oprymea 0,18 mg tabletter: vit, oval, fasade kanter med brytskåra, märkta med “P7” på båda halvorna på ena sidan.
Oprymea 0.35 mg tablets Pramipexole 
Oprymea 0,35 mg tabletter Pramipexol
White, oval, with bevelled edges, both sides scored, with imprint "P8" on both halves of one side of the tablet. 
Vit, oval, fasade kanter, brytskåra på båda sidorna, märkta med “P8” på båda halvorna på ena sidan.
Oprymea 0.088 mg tablets Pramipexole 
Oprymea 0,088 mg tabletter Pramipexol
Oprymea 0.70 mg tablets are white, round, with bevelled edges, both sides scored, with imprint "P9" on both halves of one side of the tablet. 
Oprymea 0,70 mg tabletter: vit, rund, fasade kanter, brytskåra på båda sidorna, märkta med “P9”, på båda halvorna på ena sidan.
1 tablet Oprymea 0.18 mg OR 
1 tablett Oprymea 0,18 mg eller
Doses should be increased gradually from a starting-dose of 0.264 mg of base (0.375 mg of salt) per day and then increased every 5 - 7 days. 
Dosen ökas gradvis från en initialdos på 0,264 mg bas (0,375 mg salt) per dag, med dosökning var femte till var sjunde dag.
Focus Care Pharmaceuticals B.V. Tel: +31 (0)75 612 05 11 
Tel: + 31 (0)75 612 05 11
Psychiatric disorders insomnia abnormal dreams restlessness confusion hallucinations libido disorder delusion hyperphagia paranoia mania delirium behavioural symptoms of impulse control disorders and compulsions (such as: compulsive shopping, pathological gambling, hypersexuality, binge eating) 
Psykiska störningar insomni hallucinationer onormala drömmar förvirring tvångsmässigt köpbeteende patologiskt spelberoende rastlöshet mani beteendemässiga symtom på störd impulskontroll och tvångsmässigt beteende hypersexualitet, vanföreställningar störningar av libido paranoia delirium hetsätning hyperfagi
Oprymea 3.15 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P5 on one side and 315 on the other side, with bevelled edges and possible spots. 
Oprymea 3,15 mg depottabletter är vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P5 på ena sidan och 315 på den andra sidan, med fasade kanter och eventuella fläckar.
The individual dose of pramipexole should be in the range of 0.264 mg of base (0.375 mg of salt) to a maximum of 3.3 mg of base (4.5 mg of salt) per day. 
Den individuella dosen bör vara mellan 0,264 mg bas (0,375 mg salt) och maximalt 3,3 mg bas (4,5 mg salt) per dag.
Pramipexole 
Depottablett
Each tablet contains 0.088 mg pramipexole (as 0.125 mg pramipexole dihydrochloride monohydrate). 
Varje tablett innehåller 0,088 mg pramipexol (vilket motsvarar 0,125 mg pramipexoldihydrokloridmonohydrat).
White, round, with bevelled edges, both sides scored, with imprint "P9" on both halves of one side of the tablet. 
Vit, rund, fasade kanter, brytskåra på båda sidorna, märkta med “P9”, på båda halvorna på ena sidan.
Oprymea 0.7 mg tablets Pramipexole 
Oprymea 0,7 mg tabletter Pramipexol
Frequency cannot be estimated from the available data 
Ingen känd frekvens
Oprymea 0.26 mg prolonged-release tablets Oprymea 0.52 mg prolonged-release tablets Oprymea 1.05 mg prolonged-release tablets Oprymea 1.57 mg prolonged-release tablets Oprymea 2.1 mg prolonged-release tablets Oprymea 2.62 mg prolonged-release tablets Oprymea 3.15 mg prolonged-release tablets 
Oprymea 0,26 mg depottabletter Oprymea 0,52 mg depottabletter Oprymea 1,05 mg depottabletter Oprymea 1,57 mg depottabletter Oprymea 2,1 mg depottabletter Oprymea 2,62 mg depottabletter Oprymea 3,15 mg depottabletter
2 tablets Oprymea 0.088 mg 
2 tabletter Oprymea 0,088 mg
Oprymea 0.26 mg: Each prolonged-release tablet contains 0.26 mg pramipexole (as 0.375 mg pramipexole dihydrochloride monohydrate). 
Oprymea 0,26 mg: Varje depottablett innehåller 0,26 mg pramipexol (vilket motsvarar 0,375 mg pramipexoldihydrokloridmonohydrat).
White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P13 on one side and 262 on the other side, with bevelled edges and possible spots. 
Vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P13 på ena sidan och 262 på den andra sidan, med fasade kanter och eventuella fläckar.
(eating more food than normal and more than is needed to satisfy your hunger)* - Delirium (decreased awareness, confusion, loss of reality) 
(ätande större mängder mat än normalt och mer än vad som behövs för att stilla hungern).
Oprymea 2.62 mg prolonged-release tablets Pramipexole 
Oprymea 2,62 mg depottabletter Pramipexol
White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P5 on one side and 315 on the other side, with bevelled edges and possible spots. 
Vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P5 på ena sidan och 315 på den andra sidan, med fasade kanter och eventuella fläckar.
6 tablets Oprymea 0.088 mg 
6 tabletter Oprymea 0,088 mg
4 tablets Oprymea 0.088 mg 
4 tabletter Oprymea 0,088 mg
Gastrointestinal disorders nausea constipation vomiting 
Magtarmkanalen illamående förstoppning kräkningar
Oprymea 0.18 mg tablets Pramipexole 
Oprymea 0,18 mg tabletter Pramipexol
Oprymea 0.52 mg: Each prolonged-release tablet contains 0.52 mg pramipexole (as 0.75 mg pramipexole dihydrochloride monohydrate). 
Oprymea 0,52 mg: Varje depottablett innehåller 0,52 mg pramipexol (vilket motsvarar 0,75 mg pramipexoldihydrokloridmonohydrat).
- Vision impairment. 
- synstörning.
Each prolonged-release tablet contains 2.62 mg pramipexole (as 3.75 mg pramipexole dihydrochloride monohydrate). 
Varje depottablett innehåller 2,62 mg pramipexol (vilket motsvarar 3,75 mg pramipexoldihydrokloridmonohydrat).
Oprymea 0.26 mg Oprymea 0.52 mg Oprymea 1.05 mg prolonged-release tablets 
Oprymea 0,26 mg Oprymea 0,52 mg Oprymea 1,05 mg depottabletter
If you have advanced Parkinson's disease and are also taking levodopa, you might develop dyskinesia during the uptitration of Oprymea - Dystonia (inability of keeping your body and neck straight and upright (axial dystonia)). 
Om du har avancerad Parkinsons sjukdom och även tar levodopa, kan du utveckla dyskinesi under upptitreringsperioden med Oprymea.
- Sleepiness and episodes of suddenly falling asleep - Psychosis (e.g. comparable with symptoms of schizophrenia) - Vision impairment. 
- psykos (t ex jämförbart med symtom på schizofreni).
Oprymea 0.26 mg Oprymea 0.52 mg Oprymea 1.05 mg prolonged-release tablets Pramipexole 
Oprymea 0,26 mg Oprymea 0,52 mg Oprymea 1,05 mg depottabletter Pramipexol
Ascending dose schedule of Oprymea prolonged-release tablets Week Daily dose (mg of base) 
Schema för dosökning med Oprymea depottabletter Vecka Dygnsdos (mg bas) Dygnsdos (mg salt)
Oprymea 2.62 mg prolonged-release tablets 
Oprymea 2,62 mg depottabletter
Each tablet contains 1.1 mg pramipexole (as 1.5 mg pramipexole dihydrochloride monohydrate). 
Varje tablett innehåller 1,1 mg pramipexol (vilket motsvarar 1,5 mg pramipexoldihydrokloridmonohydrat).
2 tablets Oprymea 0.18 mg 
2 tabletter Oprymea 0,18 mg eller
0.26 mg: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P1 on one side, with bevelled edges and possible spots. 
0,26 mg: Vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P1 på ena sidan, med fasade kanter och eventuella fläckar.
1.05 mg: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P3 on one side, with bevelled edges and possible spots. 
1,05 mg: Vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P3 på ena sidan, med fasade kanter och eventuella fläckar.
Oprymea 1.1 mg tablets 20 tablets: EU/1/08/469/021 30 tablets: EU/1/08/469/022 60 tablets: EU/1/08/469/023 90 tablets: EU/1/08/469/024 100 tablets: EU/1/08/469/025 
Oprymea 1,1 mg tabletter 20 tabletter: EU/1/08/469/021 30 tabletter: EU/1/08/469/022 60 tabletter: EU/1/08/469/023 90 tabletter: EU/1/08/469/024 100 tabletter: EU/1/08/469/025
The daily dose is administered in equally divided doses 3 times a day. 
Parkinsons sjukdom Dygnsdosen administreras fördelad på 3 lika doser.
What Oprymea looks like and contents of the pack Oprymea 0.26 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P1 on one side, with bevelled edges and possible spots. 
Läkemedlets utseende och förpackningsstorlekar Oprymea 0,26 mg depottabletter är vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P1 på ena sidan, med fasade kanter och eventuella fläckar.
Each prolonged-release tablet contains 1.57 mg pramipexole (as 2.25 mg pramipexole dihydrochloride monohydrate). 
Varje depottablett innehåller 1,57 mg pramipexol (vilket motsvarar 2,25 mg pramipexoldihydrokloridmonohydrat).
Oprymea 3.15 mg prolonged-release tablets 
Oprymea 3,15 mg depottabletter
Each prolonged-release tablet contains 3.15 mg pramipexole (as 4.5 mg pramipexole dihydrochloride monohydrate). 
Varje depottablett innehåller 3,15 mg pramipexol (vilket motsvarar 4,5 mg pramipexoldihydrokloridmonohydrat).
Each tablet contains 0.35 mg pramipexole (as 0.5 mg pramipexole dihydrochloride monohydrate). 
Varje tablett innehåller 0,35 mg pramipexol (vilket motsvarar 0,5 mg pramipexoldihydrokloridmonohydrat).
0.52 mg: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P2 on one side, with bevelled edges and possible spots. 
0,52 mg: Vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P2 på ena sidan, med fasade kanter och eventuella fläckar.
Oprymea 3.15 mg prolonged-release tablets Pramipexole 
Oprymea 3,15 mg depottabletter Pramipexol
Each tablet contains 0.18 mg pramipexole (as 0.25 mg pramipexole dihydrochloride monohydrate). 
Varje tablett innehåller 0,18 mg pramipexol (vilket motsvarar 0,25 mg pramipexoldihydrokloridmonohydrat).
Oprymea 0.35 mg tablets 20 tablets: EU/1/08/469/011 30 tablets: EU/1/08/469/012 60 tablets: EU/1/08/469/013 90 tablets: EU/1/08/469/014 100 tablets: EU/1/08/469/015 
Oprymea 0,35 mg tabletter 20 tabletter: EU/1/08/469/011 30 tabletter: EU/1/08/469/012 60 tabletter: EU/1/08/469/013 90 tabletter: EU/1/08/469/014
Each tablet contains 0.7 mg pramipexole (as 1 mg pramipexole dihydrochloride monohydrate). 
Varje tablett innehåller 0,7 mg pramipexol (vilket motsvarar 1 mg pramipexoldihydrokloridmonohydrat).
EU/1/08/469/011 [20 tablets] EU/1/08/469/012 [30 tablets] EU/1/08/469/013 [60 tablets] EU/1/08/469/014 [90 tablets] EU/1/08/469/015 [100 tablets] 
EU/1/08/469/011 [20 tabletter] EU/1/08/469/012 [30 tabletter] EU/1/08/469/013 [60 tabletter] EU/1/08/469/014 [90 tabletter] EU/1/08/469/015 [100 tabletter]
EU/1/08/469/021 [20 tablets] EU/1/08/469/022 [30 tablets] EU/1/08/469/023 [60 tablets] EU/1/08/469/024 [90 tablets] EU/1/08/469/025 [100 tablets] 
EU/1/08/469/021 [20 tabletter] EU/1/08/469/022 [30 tabletter] EU/1/08/469/023 [60 tabletter] EU/1/08/469/024 [90 tabletter] EU/1/08/469/025 [100 tabletter]
Oprymea 0.18 mg tablets 20 tablets: EU/1/08/469/006 30 tablets: EU/1/08/469/007 60 tablets: EU/1/08/469/008 90 tablets: EU/1/08/469/009 100 tablets: EU/1/08/469/010 
Oprymea 0,18 mg tabletter 20 tabletter: EU/1/08/469/006 30 tabletter: EU/1/08/469/007 60 tabletter: EU/1/08/469/008 90 tabletter: EU/1/08/469/009 100 tabletter: EU/1/08/469/010
Oprymea 3.15 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/050 30 prolonged-release tablets: EU/1/08/469/051 90 prolonged-release tablets: EU/1/08/469/052 100 prolonged-release tablets: EU/1/08/469/053 
Oprymea 3,15 mg depottabletter 10 depottabletter: EU/1/08/469/050 30 depottabletter: EU/1/08/469/051 90 depottabletter: EU/1/08/469/052 100 depottabletter: EU/1/08/469/053
Each prolonged-release tablet contains 1.05 mg pramipexole (as 1.5 mg pramipexole dihydrochloride monohydrate). 
Varje depottablett innehåller 1,05 mg pramipexol (vilket motsvarar 1,5 mg pramipexoldihydrokloridmonohydrat).
Each prolonged-release tablet contains 2.1 mg pramipexole (as 3 mg pramipexole dihydrochloride monohydrate). 
Varje depottablett innehåller 2,1 mg pramipexol (vilket motsvarar 3 mg pramipexoldihydrokloridmonohydrat).
Oprymea 2.1 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P4 on one side, with bevelled edges and possible spots. 
Oprymea 2,1 mg depottabletter är vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P4 på ena sidan, med fasade kanter och eventuella fläckar.
Oprymea 0.7 mg tablets 20 tablets: EU/1/08/469/016 30 tablets: EU/1/08/469/017 60 tablets: EU/1/08/469/018 90 tablets: EU/1/08/469/019 100 tablets: EU/1/08/469/020 
Oprymea 0,7 mg tabletter 20 tabletter: EU/1/08/469/016 30 tabletter: EU/1/08/469/017 60 tabletter: EU/1/08/469/018 90 tabletter: EU/1/08/469/019 100 tabletter: EU/1/08/469/020
Oprymea 1.05 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/034 30 prolonged-release tablets: EU/1/08/469/035 90 prolonged-release tablets: EU/1/08/469/036 100 prolonged-release tablets: EU/1/08/469/037 
Oprymea 1,05 mg depottabletter 10 depottabletter: EU/1/08/469/034 30 depottabletter: EU/1/08/469/035 90 depottabletter: EU/1/08/469/036 100 depottabletter: EU/1/08/469/037
Oprymea 1.05 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P3 on one side, with bevelled edges and possible spots. 
Oprymea 1,05 mg depottabletter är vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P3 på ena sidan, med fasade kanter och eventuella fläckar.
Oprymea 1.05 mg prolonged-release tablets 
Oprymea 1,05 mg depottabletter
Oprymea 1.57 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P12 on one side, with bevelled edges and possible spots. 
Oprymea 1,57 mg depottabletter är vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P12 på ena sidan, med fasade kanter och eventuella fläckar.
Nervous system disorders headache dizziness somnolance sudden onset of sleep syncope dyskinesia amnesia hyperkinesia 
Centrala och perifera nervsystemet somnolens yrsel dyskinesi huvudvärk plötsligt insomnande minnesförlustamnesi hyperkinesi synkope
patients with Parkinson's Disease treated with pramipexole. 
Klinisk effekt och säkerhet vid Parkinsons sjukdom Hos patienter leder behandling med pramipexol till symtomförbättring vid idiopatisk Parkinsons sjukdom.
Oprymea 2.1 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/042 30 prolonged-release tablets: EU/1/08/469/043 90 prolonged-release tablets: EU/1/08/469/044 100 prolonged-release tablets: EU/1/08/469/045 
Oprymea 2,1 mg depottabletter 10 depottabletter: EU/1/08/469/042 30 depottabletter: EU/1/08/469/043 90 depottabletter: EU/1/08/469/044 100 depottabletter: EU/1/08/469/045
EU/1/08/469/001[20 tablets] EU/1/08/469/002 [30 tablets] EU/1/08/469/003 [60 tablets] EU/1/08/469/004 [90 tablets] EU/1/08/469/005 [100 tablets] 
EU/1/08/469/001 [20 tabletter] EU/1/08/469/002 [30 tabletter] EU/1/08/469/003 [60 tabletter] EU/1/08/469/004 [90 tabletter] EU/1/08/469/005 [100 tabletter]
EU/1/08/469/016 [20 tablets] EU/1/08/469/017 [30 tablets] EU/1/08/469/018 [60 tablets] EU/1/08/469/019 [90 tablets] EU/1/08/469/020 [100 tablets] 
EU/1/08/469/016 [20 tabletter] EU/1/08/469/017 [30 tabletter] EU/1/08/469/018 [60 tabletter] EU/1/08/469/019 [90 tabletter] EU/1/08/469/020 [100 tabletter]
Oprymea 2.62 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/046 30 prolonged-release tablets: EU/1/08/469/047 90 prolonged-release tablets: EU/1/08/469/048 100 prolonged-release tablets: EU/1/08/469/049 
Oprymea 2,62 mg depottabletter 10 depottabletter: EU/1/08/469/046 30 depottabletter: EU/1/08/469/047 90 depottabletter: EU/1/08/469/048 100 depottabletter: EU/1/08/469/049
EU/1/08/469/042 [10 prolonged-release tablets] EU/1/08/469/043 [30 prolonged-release tablets] EU/1/08/469/044 [90 prolonged-release tablets] EU/1/08/469/045 [100 prolonged-release tablets] 
EU/1/08/469/042 [10 depottabletter] EU/1/08/469/043 [30 depottabletter] EU/1/08/469/044 [90 depottabletter] EU/1/08/469/045 [100 depottabletter]
Oprymea 0.52 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P2 on one side, with bevelled edges and possible spots. 
Oprymea 0,52 mg depottabletter är vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P2 på ena sidan, med fasade kanter och eventuella fläckar.
Oprymea 1.57 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/038 30 prolonged-release tablets: EU/1/08/469/039 90 prolonged-release tablets: EU/1/08/469/040 100 prolonged-release tablets: EU/1/08/469/041 
Oprymea 1,57 mg depottabletter 10 depottabletter: EU/1/08/469/038 30 depottabletter: EU/1/08/469/039 90 depottabletter: EU/1/08/469/040 100 depottabletter: EU/1/08/469/041
Oprymea 1.57 mg prolonged-release tablets 
Oprymea 1,57 mg depottabletter
Tell your doctor if you have or have had or develop any medical conditions or symptoms, especially any of the following: - Kidney disease - Hallucinations (seeing, hearing or feeling things that are not there). 
Tala om för din läkare om du har (har haft) eller fått några symtom, speciellt något av följande: njursjukdom.
EU/1/08/469/050 [10 prolonged-release tablets] EU/1/08/469/051 [30 prolonged-release tablets] EU/1/08/469/052 [90 prolonged-release tablets] EU/1/08/469/053 [100 prolonged-release tablets] 
EU/1/08/469/050 [10 depottabletter] EU/1/08/469/051 [30 depottabletter] EU/1/08/469/052 [90 depottabletter] EU/1/08/469/053 [100 depottabletter]
EU/1/08/469/006 [20 tablets] EU/1/08/469/007 [30 tablets] EU/1/08/469/008 [60 tablets] EU/1/08/469/009 [90 tablets] EU/1/08/469/010 [100 tablets] 
EU/1/08/469/006 [20 tabletter] EU/1/08/469/007 [30 tabletter] EU/1/08/469/008 [60 tabletter] EU/1/08/469/009 [90 tabletter] EU/1/08/469/010 [100 tabletter]
EU/1/08/469/034 [10 prolonged-release tablets] EU/1/08/469/035 [30 prolonged-release tablets] EU/1/08/469/036 [90 prolonged-release tablets] EU/1/08/469/037 [100 prolonged-release tablets] 
EU/1/08/469/034 [10 depottabletter] EU/1/08/469/035 [30 depottabletter] EU/1/08/469/036 [90 depottabletter] EU/1/08/469/037 [100 depottabletter]
EU/1/08/469/046 [10 prolonged-release tablets] EU/1/08/469/047 [30 prolonged-release tablets] EU/1/08/469/048 [90 prolonged-release tablets] EU/1/08/469/049 [100 prolonged-release tablets] 
EU/1/08/469/046 [10 depottabletter] EU/1/08/469/047 [30 depottabletter] EU/1/08/469/048 [90 depottabletter] EU/1/08/469/049 [100 depottabletter]
Oprymea 0.52 mg prolonged-release tablets Pramipexole 
Oprymea 0,52 mg depottabletter Pramipexol
Each prolonged-release tablet contains 0.26 mg pramipexole (as 0.375 mg pramipexole dihydrochloride monohydrate). 
Varje depottablett innehåller 0,26 mg pramipexol (vilket motsvarar 0,375 mg pramipexoldihydrokloridmonohydrat).
Oprymea 1.57 mg prolonged-release tablets Pramipexole 
Oprymea 1,57 mg depottabletter Pramipexol
One Oprymea 0.26 mg prolonged-release tablet on blister "Week 1". 
Dosökningsschema för Oprymea depottabletter Vecka Dygnsdos (mg) Antal tabletter En Oprymea 0,26 mg depottablett från blister ”Vecka 1”.
Oprymea 0.26 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/026 30 prolonged-release tablets: EU/1/08/469/027 90 prolonged-release tablets: EU/1/08/469/028 100 prolonged-release tablets: EU/1/08/469/029 
Oprymea 0,26 mg depottabletter 10 depottabletter: EU/1/08/469/026 30 depottabletter: EU/1/08/469/027 90 depottabletter: EU/1/08/469/028 100 depottabletter: EU/1/08/469/029
Oprymea 0.52 mg prolonged-release tablets 
Oprymea 0,52 mg depottabletter
EU/1/08/469/030 [10 prolonged-release tablets] EU/1/08/469/031[30 prolonged-release tablets] EU/1/08/469/032[90 prolonged-release tablets] EU/1/08/469/033[100 prolonged-release tablets] 
EU/1/08/469/030 [10 depottabletter] EU/1/08/469/031 [30 depottabletter] EU/1/08/469/032 [90 depottabletter] EU/1/08/469/033 [100 depottabletter]
Oprymea 1.05 mg prolonged-release tablets Pramipexole 
Oprymea 1,05 mg depottabletter Pramipexol
Oprymea 2.1 mg prolonged-release tablets Pramipexole 
Oprymea 2,1 mg depottabletter Pramipexol
EU/1/08/469/038 [10 prolonged-release tablets] EU/1/08/469/039 [30 prolonged-release tablets] EU/1/08/469/040 [90 prolonged-release tablets] EU/1/08/469/041 [100 prolonged-release tablets] 
EU/1/08/469/038 [10 depottabletter] EU/1/08/469/039 [30 depottabletter] EU/1/08/469/040 [90 depottabletter] EU/1/08/469/041 [100 depottabletter]
Each prolonged-release tablet contains 0.52 mg pramipexole (as 0.75 mg pramipexole dihydrochloride monohydrate). 
Varje depottablett innehåller 0,52 mg pramipexol (vilket motsvarar 0,75 mg pramipexoldihydrokloridmonohydrat).
st week 
Första veckan
Very rare may affect up to 1 in 10,000 people 
Mindre vanliga: kan förekomma hos upp till 1 av 100 användare Sällsynta:
EU/1/08/469/026 [10 prolonged-release tablets] EU/1/08/469/027 [30 prolonged-release tablets] EU/1/08/469/028 [90 prolonged-release tablets] EU/1/08/469/029 [100 prolonged-release tablets] 
EU/1/08/469/026 [10 depottabletter] EU/1/08/469/027 [30 depottabletter] EU/1/08/469/028 [90 depottabletter] EU/1/08/469/029 [100 depottabletter]
White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P3 on one side, with bevelled edges and possible spots. 
Vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P3 på ena sidan, med fasade kanter och eventuella fläckar.
White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P1 on one side, with bevelled edges and possible spots. 
Vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P1 på ena sidan, med fasade kanter och eventuella fläckar.
White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P12 on one side, with bevelled edges and possible spots. 
Vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P12 på ena sidan, med fasade kanter och eventuella fläckar.
- 7 prolonged-release tablets of 1.05 mg 
- 7 stycken 1,05 mg depottabletter
Do not chew, divide or crush the prolonged-release tablets. 
Depottabletten får inte tuggas, delas eller krossas.